Vyvanse, a stimulant medication for ADHD, has become the fastest-growing drug on Australia's Pharmaceutical Benefits Scheme, surpassing Ozempic. Psychiatrists are calling for stronger regulation amid concerns about misdiagnosis and overdiagnosis, with the surge linked to increased awareness through social media and misleading information from influencers. The medication was first listed on the PBS five years ago, making it the first ADHD treatment available for adults at subsidised rates. | Sunr